GC
SLXP

Guggenheim Capital’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Guggenheim Capital’s Portfolio SLXP Stock Details SLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-228,782
Closed -$39.5M – 3181
2015
Q1 		$39.5M Buy
228,782
+84,895
+59% +$12.5M 0.09% 395
2014
Q4 		$16.5M Sell
143,887
-302,472
-68% -$36.6M 0.04% 678
2014
Q3 		$69.7M Buy
446,359
+160,423
+56% +$23.3M 0.17% 103
2014
Q2 		$35.3M Sell
285,936
-29,994
-9% -$3.32M 0.09% 379
2014
Q1 		$32.7M Buy
315,930
+19,359
+7% +$1.98M 0.09% 335
2013
Q4 		$26.7M Buy
296,571
+190,860
+181% +$15.2M 0.08% 403
2013
Q3 		$7.07M Buy
105,711
+92,296
+688% +$6.36M 0.03% 945
2013
Q2 		$887K Buy
+13,415
New +$767K ﹤0.01% 2117

Other funds holding SLXP

MMG
Monetary Management Group St Louis, Missouri $419M AUM 29.55% 1-Year Est. Return

Guggenheim Capital's SLXP Position: Q2 2015 in Review

Guggenheim Capital sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q2 2015, closing a stake of 228,782 shares — an estimated $39.5M sold.

Guggenheim Capital first reported a position in SLXP in Q2 2013 and held it in 8 quarters. The position peaked at $69.7M in Q3 2014. 1 fund tracked by Wall St. Rank holds SLXP as of Q2 2015.

  • Guggenheim Capital reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q2 2015 after selling out during the quarter.
  • Guggenheim Capital sold 228,782 SALIX PHARMACEUTICALS LTD DEL shares in Q2 2015, an estimated $39.5M.
  • Guggenheim Capital first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q2 2013 and held it in 8 quarters.
  • Guggenheim Capital's SALIX PHARMACEUTICALS LTD DEL position peaked at $69.7M in Q3 2014.
  • 1 fund tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q2 2015.

Based on Guggenheim Capital's 13F filing for Q2 2015, filed 14 Aug 2015.